Literature DB >> 16997518

Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.

Tomotaka Kobayashi1, Tatsuhiro Ishida, Yurie Okada, Saori Ise, Hideyoshi Harashima, Hiroshi Kiwada.   

Abstract

The over-expression of P-glycoprotein (P-gp) has been associated with the development of multidrug resistance (MDR) in cancer cells. In this study, we examined whether transferrin receptor (Tf-R) targeted liposomes can efficiently deliver encapsulated doxorubicin (DXR) into MDR cells (SBC-3/ADM) via Tf-R-mediated endocytosis thus overcoming MDR by by-passing P-gp-mediated drug efflux. We prepared four types of liposome, i.e. untargeted and Tf-R-targeted, made of either egg-PC/cholesterol or hydrogenated egg PC/cholesterol. Only with the targeted EPC-liposome we achieved significant delivery of encapsulated DXR and increased cytotoxicity of encapsulated DXR on the MDR cells (3.5-fold higher than free DXR). Confocal microscopy and an intracellular drug-accumulation assay indicated that the targeted liposomes efficiently delivered DXR into cells where it readily accumulated in the nucleus, in both drug-sensitive and MDR cells. These findings suggest that the targeted liposomes are rapidly internalized via Tf-R-mediated endocytosis followed by release of their contents into the cytoplasm. The rapid internalization and content release, most likely facilitated by the higher fluidity of the EPC-based liposomes, may explain why only targeted EPC-liposomes were able to prevent drug efflux by P-gp and to consequently circumvent MDR. Our results indicate that in order to achieve MDR circumvention by means of liposomal encapsulation of DXR the liposomes not only need to be targeted, but also to have the proper physicochemical properties for adequate release of the drug. Furthermore, these in vitro results suggest that Tf-R targeted EPC-liposomes are a potentially useful drug delivery system to circumvent P-gp-mediated MDR of tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16997518     DOI: 10.1016/j.ijpharm.2006.08.039

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  35 in total

1.  Polyaspartamide-doxorubicin conjugate as potential prodrug for anticancer therapy.

Authors:  Chiara Di Meo; Felisa Cilurzo; Mariano Licciardi; Cinzia Scialabba; Rocchina Sabia; Donatella Paolino; Donatella Capitani; Massimo Fresta; Gaetano Giammona; Claudio Villani; Pietro Matricardi
Journal:  Pharm Res       Date:  2014-10-31       Impact factor: 4.200

Review 2.  Combination of nitric oxide and drug delivery systems: tools for overcoming drug resistance in chemotherapy.

Authors:  Jihoon Kim; Bryant C Yung; Won Jong Kim; Xiaoyuan Chen
Journal:  J Control Release       Date:  2016-12-26       Impact factor: 9.776

Review 3.  Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.

Authors:  Sharad Mangal; Wei Gao; Tonglei Li; Qi Tony Zhou
Journal:  Acta Pharmacol Sin       Date:  2017-05-01       Impact factor: 6.150

Review 4.  Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor.

Authors:  Yinghuan Li; Jie Wang; M Guillaume Wientjes; Jessie L-S Au
Journal:  Adv Drug Deliv Rev       Date:  2011-05-03       Impact factor: 15.470

5.  Argonaute2 is a potential target for siRNA-based cancer therapy for HT1080 human fibrosarcoma.

Authors:  Tatsuaki Tagami; Takuya Suzuki; Kiyomi Hirose; Jose Mario Barichello; Naoshi Yamazaki; Tomohiro Asai; Naoto Oku; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  Drug Deliv Transl Res       Date:  2011-08       Impact factor: 4.617

6.  Transferrin-targeted polymeric micelles co-loaded with curcumin and paclitaxel: efficient killing of paclitaxel-resistant cancer cells.

Authors:  Abraham H Abouzeid; Niravkumar R Patel; Can Sarisozen; Vladimir P Torchilin
Journal:  Pharm Res       Date:  2014-02-13       Impact factor: 4.200

7.  Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice.

Authors:  Tamer A Elbayoumi; Vladimir P Torchilin
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

8.  Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody.

Authors:  Tamer A ElBayoumi; Vladimir P Torchilin
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

9.  Hyaluronic acid derivative-based self-assembled nanoparticles for the treatment of melanoma.

Authors:  Yu-Jin Jin; Ubonvan Termsarasab; Seung-Hak Ko; Jae-Seong Shim; Saeho Chong; Suk-Jae Chung; Chang-Koo Shim; Hyun-Jong Cho; Dae-Duk Kim
Journal:  Pharm Res       Date:  2012-08-11       Impact factor: 4.200

Review 10.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.